Sat Nov 1 20:12:11 SGT 2014  
STD
TESTING
SINGAPORE™
    HIV Window Period
STD TESTING SINGAPORE™
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment 10 days after unprotected sex, detect HIV infection with the DNA test 28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing
Males: do not urinate for at least 4 hours before arriving
Females: testing is more accurate when you are not menstruating

HIV Window Period | STD TESTING SINGAPORE™

Summary

HIV Window Period | STD TESTING SINGAPORE™ @stdtestingsingapore_com: HIV (human immunodeficiency virus) window period, Singapore. Private & confidential service.

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
STD TESTING SINGAPORE™
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: HIV Window Period | STD TESTING SINGAPORE™
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Description

Table of Contents

HIV window period is the time from HIV infection until a HIV Test can detect any change. Within the HIV window period, the HIV Test would be negative. During this period, the HIV viral load is extremely high, thus making the person highly infectious.
  • 4 weeks after exposure, a negative 4th generation HIV ELISA Test "is very reassuring / highly likely to exclude HIV infection."
  • 12 weeks after exposure, a negative 3rd generation HIV ELISA Test "would definitively exclude HIV infection."
References HIV is the abbreviation for the human immunodeficiency virus, which causes the acquired immunodeficiency syndrome

HIV symptoms which may present in acute HIV infection:

These are nonspecific symptoms and can present with other infections; consequently, they are unreliable indicators of HIV infection.

Kaposi's sarcoma Remember, there is no HIV cure.

HIV Test

Window
period
Test
Notes Sampling Method
Time to Results
Cost / Price
0-72 hours
No test available
2 weeks (as short as 10-12 days)
HIV DNA test
  • A PCR (polymerase chain reaction) NAT (nucleic acid test) for HIV-1 proviral DNA, therefore a HIV DNA Test.
  • Method: Proviral DNA Polymerase Chain Reaction (Roche Amplicor HIV-1 DNA Test, V1.5) This test uses primers SK145 and SKCC1B to define a sequence of 155 nucleotides within a highly conserved region of the HIV-1 gag gene.
  • Usually used for the early diagnosis of HIV infection in neonates born to HIV+ mothers. As maternal antibodies circulate in the child for several months, the HIV antibody test would be positive.
  • Also used for early HIV diagnosis in adults.
Venipuncture
(Monday-Friday
before 10am)
1-2 weeks
SG$876/=
1 month
HIV combo test
Fingerprick
20 minute
HIV rapid test
SG$150/=
1 month
HIV duo test
Venipuncture

1-2 days
SG$48/=
3 months
OraQuick®
HIV oral test /
HIV saliva test /
Fingerprick
20 minute
HIV rapid test
SG$50/=
3 months
HIV blood test
Venipuncture
1-2 days
SG$12/=
HIV
confirmation
HIV western blot test
Venipuncture
1-2 weeks
SG$275/=
HIV
follow-up
HIV RNA test
Venipuncture
(Monday-Friday
before 10am)
1-2 weeks
SG$717/=

HIV ELISA (Enzyme-linked immunosorbent assay) test generations:

  1. 1st generation: HIV-1 IgG antibody
  2. 2nd generation: HIV-1 & HIV-2 IgG antibodies
  3. 3rd generation: HIV-1 & HIV-2 IgG & IgM antibodies
  4. 4th generation: HIV-1 & HIV-2 IgG & IgM antibodies and HIV p24 antigen
References HIV rapid test (20 minutes to results) Two types are available:

Note: If the clinic attendance is only for the HIV rapid test, then consultation fees are not added.

References

HIV PCR (polymerase chain reaction) NAT (nucleic acid test) HIV Risk (2009 figures)

Estimated HIV transmission risk per exposure for specific activities and events
Activity Risk-per-exposure
Vaginal sex, female-to-male, studies in high-income countries 0.04% (1:2380)
Vaginal sex, male-to-female, studies in high-income countries 0.08% (1:1234)
Vaginal sex, female-to-male, studies in low-income countries 0.38% (1:263)
Vaginal sex, male-to-female, studies in low-income countries 0.30% (1:333)
Vaginal sex, source partner is asymptomatic 0.07% (1:1428)
Vaginal sex, source partner has late-stage disease 0.55% (1:180)
Receptive anal sex amongst gay men, partner unknown status 0.27% (1:370)
Receptive anal sex amongst gay men, partner HIV positive 0.82% (1:123)
Receptive anal sex with condom, gay men, partner unknown status 0.18% (1:555)
Insertive anal sex, gay men, partner unknown status 0.06% (1:1666)
Insertive anal sex with condom, gay men, partner unknown status 0.04% (1:2500)
Receptive fellatio Estimates range from 0.00% to 0.04% (1:2500)
Mother-to-child, mother takes at least two weeks antiretroviral therapy 0.8% (1:125)
Mother-to-child, mother takes combination therapy, viral load below 50 0.1% (1:1000)
Injecting drug use Estimates range from 0.63% (1:158) to 2.4% (1:41)
Needlestick injury, no other risk factors 0.13% (1:769)
Blood transfusion with contaminated blood 92.5% (9:10)
Sources: vaginal sex;1 anal sex;2 fellatio;3 2 mother-to-child;4 other activities.5

References

  1. Boily MC et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 9(2): 118-129, 2009
  2. Vittinghoff E et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. American Journal of Epidemiology 150: 306-311, 1999
  3. Del Romero J et al. Evaluating the risk of HIV transmission through unprotected orogenital sex. AIDS 16(9): 1296-1297, 2002
  4. Townsend C et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 22: 973-981, 2008
  5. Baggaley RF et al. Risk of HIV-1 transmission for parenteral exposure and blood transfusion. AIDS 20: 805-812, 2006
  6. HIV & AIDS Information :: How transmission occurs - Estimated risk per exposure
HIV Risk (2005 figures)

Estimated per-act risk for acquisition of HIV, by exposure route*

Exposure routeRisk per 10,000
exposures
to an infected source
%
Blood transfusion900090
Needle-sharing injection-drug use670.67
Receptive anal intercourse500.5
Percutaneous needle stick300.3
Receptive penile-vaginal intercourse100.1
Insertive anal intercourse6.50.065
Insertive penile-vaginal intercourse50.05
Receptive oral intercourse†10.01
Insertive oral intercourse†0.50.005
*Estimates of risk for transmission from sexual exposures assume no condom use.
†Source refers to oral intercourse performed on a man.

References

HIV risk (2002 figures)

HIV Risk Statistics (chances of getting HIV)
HIV Risk Factors HIV Transmission Probability
Needle stick injury3 1/300
Receptive anal intercourse4 1/100
Receptive vaginal intercourse5 1/1000
Insertive vaginal intercourse4 1/2000
Insertive anal intercourse4 1/2500
Receptive fellatio with ejaculation4 1/2500
Sharing needles6 1/150

References

  1. Cardo DM, Culver DH, Ciesielski CA, et al. A Case-Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure. N Engl J Med. 1997;337:1485-1490.
  2. Katz MH, Gerberding JL. Management of occupational and nonoccupational postexposure HIV prophylaxis. Current Inf Dis Reports. 2002;4:543-549.
  3. Gerberding JL. Prophylaxis for Occupational Exposure to HIV. Ann Intern Med. 1996;6:497-501
  4. Vitinghoff E, Douglas J, Judon F, et al. Per-Contact Risk of Human Immunodificiency Virus Transmision between Male Sexual Partners. Am J Epidemiol. 1999;150:306-311.
  5. Peterman TA, Stoneburner RL, Allen JR, et al. Risk of Human Immunodeficiency Virus Transmission From Heterosexual Adults With Transfusion-Associated Infections. JAMA. 1988;259:55-58. [Erratum. JAMA. 1989;262:502]
  6. Kaplan EH, Heimer R. A Model-Based Estimate of HIV Infectivity via Needle Sharing. J Acquir Immune Defic Syndr. 1992;5:1116-1118.
HIV prevention / HIV PEP (post-exposure prophylaxis) treatment can prevent you from getting an HIV infection, and turning HIV positive.

Individuals are eligible for HIV PEP Treatment if all the following criteria are met:

  1. less than 72 hours has elapsed since exposure;
    and
  2. the exposed individual is not known to be HIV infected;
    and
  3. the person who is the source of exposure is HIV infected or has unknown HIV status;
    and
  4. mucous membrane or non-intact skin was exposed to a potentially infectious body fluid;
Prompt antiviral therapy may reduce the risk of HIV transmission by as much as 80%.

For optimal efficacy, antiretroviral therapy should be started as soon as possible, ideally within 1 hour of exposure. So that you can remain HIV negative.

The medications and dosages are the same as those used for lifelong treatment of HIV patients. However, for HIV PEP treatment, it is taken for only a month.

Algorithm for evaluation and treatment of possible nonoccupational HIV exposures
References Drugs commonly used in HIV PEP: References TORCH

TORCH complex is a medical acronym for a set of perinatal infections (i.e. infections that are passed from a pregnant woman to her fetus), that can lead to severe fetal anomalies or even fetal loss.
Other agents are:

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline Event / Available resources
HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception
(females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception
(females only)
2 weeks HIV DNA PCR test
1 month 20 minute SD Bioline HIV Ag/Ab Combo HIV rapid test:
- Fingerprick blood sampling.
3 months 20 minute OraQuick® HIV rapid test:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

References


Latest News

HIV: new drugs, new guidelines
Fri, 31 Oct 2014 20:53:14 +0100 | Current Opinion in Infectious Diseases
Purpose of reviewThis review discusses recent changes in HIV treatment guidelines, focussing on the optimal time for starting antiretroviral therapy (ART) in chronic asymptomatic infection, and treatment options for ART-naïve patients.

Africa: Johannes Hunger Appointed As Head of Strategic Information
Fri, 31 Oct 2014 15:22:17 +0100 | AllAfrica News: HIV-Aids and STDs
[Global Fund]Geneva -The Global Fund to Fight AIDS, Tuberculosis and Malaria announced the appointment of Johannes Hunger, an expert on strategic and policy planning in global health, as Head of Strategic Information. (Source: AllAfrica News: HIV-Aids and STDs)

What Couples Say about Their Recovery of Sexual Intimacy after Prostatectomy: Toward the Development of a Conceptual Model of Couples' Sexual Recovery after Surgery for Prostate Cancer
Fri, 31 Oct 2014 15:10:18 +0100 | The Journal of Sexual Medicine
ConclusionsCouples' sexual recovery requires addressing sexual function, feelings about losses, and relationship simultaneously. Perioperative education should emphasize the roles of nerve damage in ED and grief and mourning in sexual recovery. Wittmann D, Carolan M, Given B, Skolarus TA, Crossley H, An L, Palapattu G, Clark P, and Montie JE. What couples say about their recovery of sexual intimacy after prostatectomy: Toward the development of a conceptual model of couples' sexual recovery after surgery for prostate cancer. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

Zimbabwe: ARM Advocates With the Appropriate Facts So That They Can Drive Change in Their Own Countries
Fri, 31 Oct 2014 15:06:11 +0100 | AllAfrica News: HIV-Aids and STDs
[What'sUpHIV]Maureen Milanga, a staffer at Health GAP in Keyna and an alumna of the AVAC Advocacy Fellows program, presented a poster demonstrating how advocates from Kenya, Zimbabwe and Nigeria were able to influence their countries by strategically raising their voices to increase demand for key interventions. (Source: AllAfrica News: HIV-Aids and STDs)

Africa: A Reminder of Scientific Progress (Past, Present and Future)
Fri, 31 Oct 2014 15:06:03 +0100 | AllAfrica News: HIV-Aids and STDs
[What'sUpHIV]A man caught my eye this week. It's somewhat fitting that a symbol of "human endeavour" (per the artist) is bearing witness to this week's HIV R4P Conference - itself a testimony to ongoing global efforts to push the boundaries of HIV prevention science. (Source: AllAfrica News: HIV-Aids and STDs)

Africa: So When Will the Next Big Thing Be Available for General Use?
Fri, 31 Oct 2014 15:02:25 +0100 | AllAfrica News: HIV-Aids and STDs
[What'sUpHIV]The one question research scientists dread most - but one which journalists are obliged to ask - is, "So when will this be available for general use?" (Source: AllAfrica News: HIV-Aids and STDs)

Africa: HIV Self-Test Kit Coming Soon
Fri, 31 Oct 2014 14:02:34 +0100 | AllAfrica News: HIV-Aids and STDs
[What'sUpHIV]If you like movies at all, by now you will have seen - many times - the scene in romantic comedies in which a woman walks into her bathroom to perform a simple test which will tell her (with a high degree of accuracy) whether or not she is pregnant. (Source: AllAfrica News: HIV-Aids and STDs)

Uganda: Poor Roads Disrupt HIV Patients' Access to Treatment
Fri, 31 Oct 2014 13:47:32 +0100 | AllAfrica News: HIV-Aids and STDs
[Key Correspondents]Poor roads in Uganda, especially at landing sites at Kigugo Island, are making it difficult for HIV positive patients to access antiretroviral treatment at St Francis Hospital in Nkokonjeru. (Source: AllAfrica News: HIV-Aids and STDs)

Ebola virus disease – Mali
Fri, 31 Oct 2014 13:45:00 +0100 | WHO Disease Outbreaks
On 23 October 2014, WHO was notified by Mali's Ministry of Health of a laboratory-confirmed case of infection with Ebola Virus Disease (EVD). This is the first EVD case in Mali. The case is a 2-year-old female who developed symptoms, presumably on 19 October 2014, while in Beuila, Guinea and then travelled across by road to Mali. On 20 October 2014, the patient was admitted to a healthcare facility in Kayes, Mali. On 21 October 2014, she was referred to the Fousseyni Daou Hospital in Kayes. On 22 October 2014, samples for EVD were taken and analysed at the Center for TB and AIDS Research in Mali. Samples came back positive for EVD. Confirmation of test results is being carried out at the Centers for Disease Control and Prevention (CDC) in Atlanta and at Institute Pasteur de Dakar Senegal. ...

Africa: How to Make Sure Your Research Centre Doesn't Get Burnt Down
Fri, 31 Oct 2014 13:26:27 +0100 | AllAfrica News: HIV-Aids and STDs
[What'sUpHIV]Crossroads in Cape Town is your classic African "tough neighbourhood". It is a shanty town - a slum. So how do you go about getting volunteers from a place like that - a place in which all authority is usually viewed with doubt and suspicion - to participate in clinical trial which involves such potentially sensitive interventions as "vaginal rings", "vaginal gels" and "vaginal microbicides"? (Source: AllAfrica News: HIV-Aids and STDs)